Author
Therapure Biopharma (Canada)ORCID 0000-0001-8449-0649Unclaimed ORCID profile · follow to get notified of new preprints
Mutual co-authors in cluster
3 papers
Recent·Most cited
Jessica Desjardins, Julian Bowlan, Cynthia Bernier…·Jordan T.F. Young
This study identifies synthetic lethal interactions between cancer drivers and tractable targets using CRISPR screens and cancer dependency data, offering new drug targets for therapy.
Mark E. Orcholski, Nancy Laterreur, Wardah Masud…·Raquel Cuella-Martin
This study identifies on-target resistance mechanisms to WRN inhibitors in MSI cancers using functional genomics and shows how to improve therapeutic durability through drug selection and combination strategies.
Isabel Soria‐Bretones, Matias Casás‐Selves, Elliot Goodfellow…·Michal Zimmermann
This study shows neuroblastoma cells are hypersensitive to PLK4 inhibitor RP-1664 due to dual mechanisms of centriole loss and amplification, leading to cell death.